Maze interim chief Charles Homcy passes baton to Jason Coloma; William Collier tapped as CEO of Arbutus
→ Four months into Maze Therapeutics’ launch, Charles Homcy is passing the startup’s reins to another Third Rock colleague. Jason Coloma, the current COO, is leaving his role at the VC firm to become full-time CEO on a mission to translate genetic insights into new medicines. Equipped with a whopping $191 million with support from Arch, Maze’s big idea is to find and target genetic modifiers that play a role in Mendelian diseases caused by another gene. Coloma, a Roche/Genentech vet seasoned in business development, was CBO at Corvus Pharmaceuticals before joining Third Rock in 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.